Medicure Inc.

Climate Impact & Sustainability Data (2023)

Short-term Goals:

Dependence on a single product (AGGRASTAT®) for a significant portion of revenue.
Increased competition from generic versions of AGGRASTAT® and ZYPITAMAG®.
Intense competition in the pharmaceutical market.
Consolidation in the healthcare industry leading to pricing pressures.
Government regulations impacting the availability of pharmacy drugs.
Risks inherent in providing pharmacy services, including product liability.
Inability to expand product offerings due to limited financial capacity.
Difficulty in obtaining regulatory approvals for products under development.
Limited manufacturing experience and marketing resources.
Limited product liability insurance.
Difficulty in protecting intellectual property rights.
Stringent governmental regulations.
Potential for legal proceedings.
Indemnification obligations to directors and senior management.
Exposure to foreign exchange movements.
Need to raise additional capital, potentially leading to dilution.
Material weaknesses in financial reporting and review process (remediated in 2023).

Diversifying revenue streams through ZYPITAMAG® and Marley Drug.
Implementing cost-saving measures.
Developing and implementing a new clinical, product, and regulatory strategy for AGGRASTAT®.
Developing additional generic cardiovascular products.
Acquiring Marley Drug to expand into the specialty pharmacy market.
Launching a national direct-to-consumer e-commerce pharmacy platform.
Exploring acquisitions or licensing of other commercial products.
Strengthening internal controls and financial reporting processes.
Hiring a new CFO and Controller with relevant experience.
Obtaining cybersecurity insurance.

Climate Change Data